INTS
INTENSITY THERAPEUTICS, INC.

2,227
Mkt Cap
$12.51M
Volume
3,677.00
52W High
$43.50
52W Low
$4.50
PE Ratio
-0.65
INTS Fundamentals
Price
$4.63
Prev Close
$4.63
Open
$4.69
50D MA
$5.55
Beta
0.00
Avg. Volume
30,423.17
EPS (Annual)
-$8.56
P/B
1.18
Rev/Employee
$0.00
$2.10
Loading...
Loading...
News
all
press releases
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award PR Newswire...
PR Newswire·7d ago
News Placeholder
More News
News Placeholder
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update PR...
PR Newswire·14d ago
News Placeholder
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Intensity Therapeutics Inc. (INTS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks·20d ago
News Placeholder
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·1mo ago
News Placeholder
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update PR Newswire SHELTON, Conn., March 27, 2026 Raised over $20 million in gross...
PR Newswire·2mo ago
News Placeholder
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US PR Newswire SHELTON, Conn...
PR Newswire·2mo ago
News Placeholder
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical...
PR Newswire·2mo ago
News Placeholder
Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement PR Newswire SHELTON, Conn...
PR Newswire·3mo ago
News Placeholder
Why Did INTS Stock Plummet 25% Today?
Intensity Therapeutics announced a 1-for-25 reverse stock split, consolidating every 25 existing shares into a single new share.
Stocktwits·3mo ago
News Placeholder
Intensity Therapeutics Announces Reverse Stock Split
Intensity Therapeutics Announces Reverse Stock Split Intensity Therapeutics Announces Reverse Stock Split PR Newswire SHELTON, Conn., Feb. 13, 2026 Intensity's common stock is expected to begin...
PR Newswire·3mo ago
<
1
2
...
>

Latest INTS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.